The startup provides contract development services for preclinical and clinical drug projects, specializing in the supply of ready-to-inject adipose-derived allogeneic stem cells. This offering enables healthcare companies to lower manufacturing costs and improve the affordability of cell therapies.
Funding
$18.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cell-based therapies present manufacturing complexities and regulatory hurdles due to their nature as living drugs, requiring specialized expertise in cell culture and adherence to stringent controls. Existing manufacturing processes may not be suitable for industrial scale-up, and navigating diverse regulatory pathways across different countries can be challenging for developers.
Solution
Cell-Easy is a science-driven Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy, offering customized process development, GMP manufacturing, and analytical services. The company supports developers of advanced therapy medicinal products (ATMPs) by providing expertise in cell culture, process development, and regulatory compliance. Cell-Easy's services cover the entire ATMP development lifecycle, from cell banking and process optimization to GMP manufacturing and quality control. By combining scientific knowledge with regulatory-controlled CDMO services, Cell-Easy helps translate laboratory concepts into successful clinical trials, offering solutions that meet product specifications and regulatory standards.
Target Audience
Cell-Easy serves biotech and pharmaceutical companies, as well as academic institutions, involved in the development of cell-based therapies for immuno-oncology and regenerative medicine.
Features
- GMP cell banking services, including creation and storage of primary, master, and working cell banks under ICH guidelines
- Process development and optimization, including upstream and downstream process development, analytical method development, and scale-up
- GMP manufacturing of cell-based therapies in a state-of-the-art facility authorized by the National French regulatory Agency (ANSM)
- Quality control services, including cell characterization, safety testing, and batch release
- CMC and regulatory support, including program diagnostics, technical support, and preparation of regulatory submissions (e.g., IND)
- Expertise in a variety of cell types, including T cells, NK cells, MSCs and iPSCs
- Capabilities for both autologous and allogeneic cell therapies